- Home
- CODX vs AYTU Comparison
CODX vs AYTU Comparison
Compare CODX & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CODX
- AYTU
- Stock Information
- Founded
- CODX 2013
- AYTU N/A
- Country
- CODX United States
- AYTU United States
- Employees
- CODX N/A
- AYTU N/A
- Industry
- CODX Medical/Dental Instruments
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- CODX Health Care
- AYTU Health Care
- Exchange
- CODX Nasdaq
- AYTU Nasdaq
- Market Cap
- CODX 9.8M
- AYTU 9.6M
- IPO Year
- CODX 2017
- AYTU N/A
- Fundamental
- Price
- CODX $0.28
- AYTU $2.10
- Analyst Decision
- CODX Buy
- AYTU
- Analyst Count
- CODX 2
- AYTU 0
- Target Price
- CODX $5.50
- AYTU N/A
- AVG Volume (30 Days)
- CODX 462.7K
- AYTU 621.9K
- Earning Date
- CODX 08-07-2025
- AYTU 05-14-2025
- Dividend Yield
- CODX N/A
- AYTU N/A
- EPS Growth
- CODX N/A
- AYTU N/A
- EPS
- CODX N/A
- AYTU N/A
- Revenue
- CODX $3,497,583.00
- AYTU $81,659,000.00
- Revenue This Year
- CODX N/A
- AYTU N/A
- Revenue Next Year
- CODX $42.11
- AYTU $8.68
- P/E Ratio
- CODX N/A
- AYTU N/A
- Revenue Growth
- CODX N/A
- AYTU 0.41
- 52 Week Low
- CODX $0.23
- AYTU $0.95
- 52 Week High
- CODX $2.23
- AYTU $2.96
- Technical
- Relative Strength Index (RSI)
- CODX 43.19
- AYTU 60.77
- Support Level
- CODX $0.26
- AYTU $1.97
- Resistance Level
- CODX $0.29
- AYTU $2.17
- Average True Range (ATR)
- CODX 0.02
- AYTU 0.14
- MACD
- CODX 0.00
- AYTU 0.00
- Stochastic Oscillator
- CODX 26.83
- AYTU 58.33
About CODX Co-Diagnostics Inc.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.